By Stephen Nakrosis

 

Arrowhead Pharmaceuticals Inc. on Monday said it entered an exclusive license agreement with GlaxoSmithKline which will see GSK develop and commercialize Arrowhead's ARO-HSD.

Arrowhead said ARO-HSD is an "investigational RNA interference therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis."

Arrowhead will receive an upfront payment of $120 million. Arrowhead is also eligible for additional payments tied to future trials and regulatory approval, as well as for commercial milestone payments and royalties, according to the companies.

GlaxoSmithKline will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead, the companies said.

The deal is expected to close in the first quarter of next year.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

November 22, 2021 16:40 ET (21:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Glaxosmithkline Charts.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Glaxosmithkline Charts.